

Tele No.011-23236965  
Fax.No.011-23236973

**F. No. ND/CT/24/000037**  
**Government of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organization**  
**(New Drugs Division)**

FDA Bhawan, Kotla Road,  
New Delhi-11 0002

To  
M/s Glenmark Pharmaceuticals Ltd.,  
Glenmark House, of B2 Mahalaxmi Chambers 22,  
Bhula Bhai Desai Road Mumbai, (India)- 400026

Subject: Application for grant of permission to conduct Phase-2 Clinical trial titled- "A Phase 2, Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate Efficacy and Safety of New Topical Formulations in the Treatment of Androgenetic Alopecia in Men" vide protocol no. GPL/CT/2024/001/II, version 1.0, dated 14<sup>th</sup> May 2024.

Sir,

With reference to your application no. **ND/CT04/FF/2024/43358** dated **16.05.2024**; please find enclosed herewith the permission in **Form CT-06**, vide no. **CT/ND/19/2024** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

**RAJEEV SINGH**  
**RAGHUVANSHI**  
**(Dr. Rajeev Singh Raghuvanshi)**  
**Drugs Controller General (India)**

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: cn=RAJEEV SINGH RAGHUVANSHI, o=CENTRAL DRUGS STANDARD  
CONTROL ORGANISATION, ou=CENTRAL DRUGS STANDARD  
CONTROL ORGANISATION,  
2.5.4.20=4237189801c9981bb5a263a4a73d025ff4b11b6  
80a91f06773480400a43ee361b, postalCode=110002,  
st=Delhi,  
serialNumber=65715e470940985d8f03bdc902d0e1fe73  
cfa12a1a126ea94fa5701124a19013, cn=RAJEEV SINGH  
RAGHUVANSHI  
Date: 2024.09.18 14:18:54 +05'30'

**Conditions of permission**

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in *accordance* with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be

intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.
- (xix) **The firm should spell out the protocol to the patient who suffers an adverse event and how they will be managed and it should be uniform across all the centers.**
- (xx) **The trials sites should be geographically distributed with 50% Govt. institutes throughout the country.**

**FORM CT-06***(See rules 22, 25, 26, 29 and 30)***PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR  
INVESTIGATIONAL NEW DRUG**

The Central Licensing Authority hereby permits **M/s Glenmark Pharmaceuticals Ltd., Glenmark House, of B2 Mahalaxmi Chambers 22, Bhula Bhai Desai Road Mumbai, (India)- 400026 Telephone: 2240189999, Fax: 2240189988 E-Mail: kishansingh.kaira@glenmarkpharma.com** to conduct clinical trial of the new drug as per Protocol Number: **Protocol no. GPL/CT/2024/001/II, version 1.0, dated 14<sup>th</sup> May 2024** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:

<b>Names of the new drug or investigational new drug:</b>	<ul style="list-style-type: none"> <li>• <b>Clascoterone 7.5% w/w and Minoxidil 5% w/w Topical Solution</b></li> <li>• <b>Clascoterone 7.5% w/w and Latanoprost 0.03% w/w Topical Solution</b></li> </ul>	
<b>Therapeutic class:</b>	<b>Topical Treatment of Androgenetic Alopecia</b>	
<b>Dosage form:</b>	Topical Solution	
<b>Composition:</b>	<ul style="list-style-type: none"> <li>• <b>Clascoterone 7.5% w/w and Minoxidil 5% w/w Topical Solution</b> Each gm of solution contains: - Clascoterone (75 mg) and - Minoxidil (50 mg)</li> <li>• <b>Clascoterone 7.5% w/w and Latanoprost 0.03% w/w Topical Solution</b> Each gm of solution contains: - Latanoprost (0.3 mg) and - Clascoterone (75 mg)</li> </ul>	
<b>Indications:</b>	Treatment of Androgenetic Alopecia (Male pattern hair loss)	
<b>Details of clinical trial sites-</b>		
<b>Sr. No.</b>	<b>Name of Principal Investigator &amp; Trial Sites</b>	<b>Ethics Committee Name/ Registration Number</b>
1.	<b>Dr. Rajiv Sharad Joshi,</b> C.L.A.I.M.S. Private Limited 27 MIDC Commercial Premises, 5th Floor, 17th Road, MIDC, Andheri East, Mumbai: 400093	Independent ethics committee, 27 MIDC Commercial Premises, 5th Floor, 17th Road, MIDC, Andheri East, Mumbai: 400093 <b>ECR/245/Indt/MH/2015/RR-22</b>
2	<b>Dr. Sonal Mahadev Shendkar</b> Lifepoint Multispeciality Hospital, 145/1 Mumbai Bangalore Highway, Near Hotel Sayaji, Wakad, Pune-411057	LPR Ethics Committee, Lifepoint Multispeciality Hospital, 145/1 Mumbai Bangalore Highway, Near Hotel Sayaji, Wakad, Pune-411057 <b>ECR/751/Inst/MH/2015/RR-21</b>
3	<b>Dr. Suneel Chandrakant Vartak</b> Assured Care Plus Hospital, Star	Institutional Ethics Committee Assured Care Plus Hospital

	Plus Complex, Lam Road, 4th & 5th Floor, Near Muktidham Temple, Opp. NMC Divisional Office, Nashik Road, Nashik 422101.	4th And 5th Floor Star Plus Complex Lam Road, Near Muktidham Temple, Opp NMC Divisional Office Nskrd Nashik Maharashtra - 422101 India <b>ECR/1756/Inst/MH/2022</b>
4	<b>Dr. Raj Kumar Kothiwala</b> Department of dermatology, venereology & leprosy, Jawaharlal Nehru Medical College, Kala Bagh, Ajmer-305001, Rajasthan	Institutional Ethics Committee, Jawaharlal Nehru Medical College, Kala Bagh, Ajmer, Rajasthan-305001 India <b>ECR/1156/Inst/RJ/2018/RR-22</b>

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

**RAJEEV SINGH**  
**RAGHUVANSHI**

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL  
ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL  
ORGANISATION,  
2.5.4.20=f2d7189b1c0981bba2e3a4a73d025ff4b11b680a91f0877  
3480402a43cc361b, postalCode=110002, st=Delhi,  
serialNumber=627F5c42B4008c6883b6c90080e1f673c612a1a12  
6ea94a570172419013, cn=RAJEEV SINGH RAGHUVANSHI  
Date: 2024.09.18 16:19:10 +05'30'

**(Dr. Rajeev Singh Raghuvanshi)**  
**Central Licensing Authority**  
**Stamp**

**New Delhi**